Search hospitals > Iowa > West Des Moines

Methodist West Hospital

Claim this profile
West Des Moines, Iowa 50266
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Breast cancer
Conducts research for Cancer
Conducts research for Ovarian Cancer
206 reported clinical trials
2 medical researchers
Photo of Methodist West Hospital in West Des MoinesPhoto of Methodist West Hospital in West Des MoinesPhoto of Methodist West Hospital in West Des Moines

Summary

Methodist West Hospital is a medical facility located in West Des Moines, Iowa. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Cancer, Ovarian Cancer and other specialties. Methodist West Hospital is involved with conducting 206 clinical trials across 374 conditions. There are 2 research doctors associated with this hospital, such as Joshua Lukenbill and Robert J. Behrens.

Area of expertise

1Lung Cancer
Global Leader
Methodist West Hospital has run 31 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage II
Stage III
2Breast Cancer
Global Leader
Methodist West Hospital has run 30 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
ER positive
HER2 positive

Top PIs

Clinical Trials running at Methodist West Hospital

Lung Cancer
Melanoma
Cutaneous Melanoma
Non-Small Cell Lung Cancer
Bladder Cancer
Prostate Cancer
Pancreatic Carcinoma
Multiple Myeloma
Pancreatic Cancer
Small Cell Lung Cancer
Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Image of trial facility.

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Methodist West Hospital?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security